Related Experiment Video

Updated: Aug 15, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Current and future strategies for treating metastatic pancreatic cancer

Jordan D Berlin1

  • 1Gastrointestinal Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, USA.

Clinical Advances in Hematology & Oncology : H&O
|September 16, 2005
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Related Experiment Videos

Last Updated: Aug 15, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Articles linked to this work by shared authors, journal, and citation graph.

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

The New England journal of medicine·2026

Choice of oncologist and influencing factors: analysis of the Pancreatic Cancer Action Network registry.

The oncologist·2025

Protected Time, Resources, and Expectations for Academic Oncology Clinical Research Physicians.

Journal of the National Comprehensive Cancer Network : JNCCN·2025

Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study.

Journal of the National Comprehensive Cancer Network : JNCCN·2024

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.

Journal for immunotherapy of cancer·2022

Artificial intelligence in prostate cancer diagnosis and management: state-of-the-art approaches and emerging innovations.

Clinical advances in hematology & oncology : H&O·2026

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026

Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer.

Clinical advances in hematology & oncology : H&O·2026

TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.

The Journal of experimental medicine·2026

Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC.

Molecular cancer therapeutics·2026

Toward Fit-for-Purpose Data for Drug Assessment in Non-small Cell Lung Cancer: A Core Dataset.

Clinical pharmacology and therapeutics·2026

Regulation of the lncRNA NEAT1 by p53-ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC.

Molecular oncology·2026

Payload-Free [89Zr]Zr-DFO*-sq-Enfortumab ImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer.

Molecular pharmaceutics·2026

Preclinical Evaluation of [68Ga]Ga-CS03 as a Novel GPC3-Targeted Probe for Imaging GPC3 in Hepatocellular Carcinoma Models.

Molecular pharmaceutics·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us